NCT06167694招募中1 期
A Multicenter, Open Phase Ib/II Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-8080 in Combination With Dalpiciclib Isethionate Tablets in Patients With ER-positive, HER2-negative Unresectable or Metastatic Breast Cancer
Shandong Suncadia Medicine Co., Ltd.2 个研究点 分布在 1 个国家目标入组 146 人开始时间: 2023年12月20日最近更新:
适应症
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 146
- 试验地点
- 2
- 主要终点
- Dose-limiting toxicity (DLT)
研究概览
简要总结
This is a multicenter, open phase Ib/II clinical study, which is divided into two phases: dose exploration and efficacy expansion. Participants entering the study will receive HRS-8080 combined with Dalpiciclib Isethionate Tablets therapy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Women aged 18-75 years with both ends included.
- •ECOG Physical status 0-1 points.
- •Patients with histologically confirmed metastatic or locally advanced breast cancer.
- •Dose-exploration stage: advanced stage has received at least 1 line of endocrine therapy progression in the past, efficacy extension stage: has not received any systemic treatment for advanced disease
- •Antitumor therapy with radiographically confirmed disease progression or receiving advanced first-line standard endocrine therapy with no clinical or radiographically confirmed disease progression.
- •At least one measurable extracranial lesion must be present.
- •Expected survival >3 months.
- •The functional level of the organ must meet the requirements of the test.
- •Fertile female subjects must consent to use highly effective contraception during the study treatment period and for 7 months after the end of the study treatment period; Fertile female subjects must be negative for serum HCG within 7 days prior to study enrollment and must be non-lactating.
- •Volunteer to participate in this clinical trial, be willing and able to follow clinical visit and study related procedures, understand study procedures and have signed informed consent.
排除标准
- •Symptoms of visceral metastasis.
- •Previous treatment did not meet trial requirements.
- •Received nitrosourea or mitomycin within 6 weeks before the first dose in this study; Received major organ surgery, cytotoxic drugs, immunotherapy, targeted therapy, anti-tumor traditional Chinese medicine or other clinical investigational drugs within 4 weeks before the first medication; He received endocrine therapy and palliative radiotherapy within 2 weeks before the first dose.
- •Less than 14 days after the first dose of CYP3A4; CYP3A4 is treated with a strong inducer <28 days from the date of first administration.
- •Patients with active (untreated or clinically symptomatic) brain metastases, cancerous meningitis, spinal cord compression, or a history of primary tumors of the central nervous system.
- •A history of clinically severe cardiovascular disease.
- •Patients with uncontrolled tumor-related pain as judged by the investigator.
- •Those who received immunosuppressive agents or systemic hormone therapy for immunosuppression within 2 weeks prior to the first dose.
- •The damage caused by the subject receiving other treatments has been recovered.
- •Severe infection occurred within 4 weeks prior to the second dose.
- •The first study investigated the occurrence of arteriovenous thrombosis within 6 months prior to medication.
- •Patients with clinically significant endometrial abnormalities.
- •Untreated active hepatitis.
- •Subjects had other malignancies within the past 5 years or currently.
- •Have an inherited or acquired bleeding tendency.
- •History of active autoimmune disease, immune deficiency, and autoimmune disease.
- •One of the many factors that affect oral medications.
- •Subjects are acutely infected or have active TB and require medication.
- •Known allergy to HRS-8080 ingredient, Dalpiciclib and ingredient.
- •Pregnant and lactating women or women planning to become pregnant during the study period.
- •There is a clear history of neurological or psychiatric disorders and the subjects have a history of psychotropic substance abuse or drug use.
- •The presence of other serious physical or mental illnesses or abnormalities in laboratory tests that may increase the risk of participating in the study or interfere with the study results, as well as patients deemed unsuitable for participation in this study by the investigator.
研究组 & 干预措施
Treatment group A
Experimental
干预措施: HRS-8080; Dalpiciclib Isethionate Tablets (Drug)
结局指标
主要结局
Dose-limiting toxicity (DLT)
时间窗: About 2 years
Maximum tolerated dose (MTD)
时间窗: About 2 years
Recommended phase II dose (RP2D)
时间窗: About 2 years
Safety endpoints: Incidence and severity of adverse events (AEs) and serious adverse events (SAEs)
时间窗: About 2 years
Outcome endpoint: Objective Response Rate (ORR)
时间窗: About 2 years
次要结局
- Steady-state valley concentration (Cmin,ss)(About 2 years)
- Duration of response (DoR)(About 2 years)
- Disease control rate (DCR)(About 2 years)
- Best overall response (BOR)(About 2 years)
- Clinical benefit rate (CBR)(About 2 years)
- Progression-free survival (PFS)(About 2 years)
- Steady-state peak concentration (Cmax,ss)(About 2 years)
- Steady-state peak time (Tmax,ss)(About 2 years)
- Steady-state blood drug concentration-time curve area (AUCss)(About 2 years)
研究者
研究点 (2)
Loading locations...
相似试验
终止
1 期
APG-1387 Plus Chemotherapy in Advanced Pancreatic AdenocarcinomaAdvanced Pancreatic CancerNCT04643405Ascentage Pharma Group Inc.21
招募中
1 期
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)GliomaNCT01906385Plus Therapeutics55
尚未招募
1 期
Safety and Efficacy of Adebrelimab Plus Irinotecan Liposome (II) With or Without Famitinib in ES-SCLC Pre-treated With ImmunotherapyExtensive-stage Small-cell Lung CancerNCT06332950Baohui Han80
已完成
不适用
To Evaluate the Efficacy and Safety of Tislelizumab in Combination With Lenvatinib in Participants With Selected Solid TumorsNCT05014828BeiGene58
招募中
1 期
A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With NSCLCNon-small Cell Lung Cancer (NSCLC)NCT06754930Suzhou Suncadia Biopharmaceuticals Co., Ltd.400